Comparison of Methods for Removing Large Benign Broad-based Epithelial Neoplasms of the Colon: ESD and EMR.
Launched by PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY · Jun 19, 2025
Trial Information
Current as of June 30, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Objective of the study: to prospectively compare the immediate, immediate and remote results of endoscopic mucosal resection through an endoscope and endoscopic submucosal dissection performed for non-invasive large-sized (20 mm or more) broad-based epithelial lesions of the colon.
Study objectives:
1. To evaluate the accuracy of ultra-high-resolution colonoscopy in white, ultra-clear and narrow-spectrum light with magnification in predicting the histological structure and risks of invasion of large-sized broad-based epithelial lesions of the colon.
2. To conduct a comparative assessment ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient with benign non-invasive epithelial formations of the colon on a broad base (Is and II types), 20-60 mm in size
- • Age ≥ 18 years.
- • Signed informed voluntary consent for colonoscopy and removal of formations using the studied methods of EMR and ESD
- Exclusion Criteria:
- • . More than one large epithelial lesion on a broad base
- • Colon lesion less than 20 mm and more than 60 mm
- • Recurrent lesion.
- • Reasonable suspicion of an invasive lesion (cancer), including one with submucosal invasion based on the results of preoperative assessment (NICE - 3; JNET - 3; Kudo - Vn).
- • Presence of widespread malignant tumour in any part of the colon.
- • Use of other methods of endoscopic lesion removal.
- • IBD.
- • Infectious disease requiring systemic therapy
- • Patient on haemodialysis
- • Uncorrectable coagulopathy (INR\> 1.5), inability to discontinue antithrombotic drugs.
- • Refusal to participate in the study. 12. General contraindications to endoscopic examination.
About Pirogov Russian National Research Medical University
Pirogov Russian National Research Medical University is a prestigious academic institution dedicated to advancing medical science and education in Russia. Renowned for its commitment to high-quality research and innovation, the university plays a pivotal role in clinical trials aimed at improving healthcare outcomes. With a multidisciplinary approach, it fosters collaboration among leading experts in various medical fields, ensuring the development of safe and effective therapeutic interventions. The institution is focused on translating research findings into clinical practice, thereby contributing significantly to the advancement of medical knowledge and patient care both nationally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Moscow, , Russian Federation
Patients applied
Trial Officials
Evgeny Gorbachev
Study Chair
Pirogov Russian National Research Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported